Tag Archives: 2011

Uncertain Outlook for Pharma and Biotech Deals Following 'Turbulent' 2011

Peter Young, President and Managing Director of international investment bank Young & Partners, looks at what lies ahead for pharma and biotech following a turbulent 2011. The business outlook for pharma companies for the rest of 2012 and beyond is mixed, as pharma companies struggle to realign themselves to a new business model that will […]
Posted in Global, Guest Blog, leadership, Strategy | Also tagged , , , , | Leave a comment

New Year Night Stalkers: What Will Keep the C-Suiters Awake in 2011

New Year Night Stalkers Eight Strategic Issues that Should Keep “C Suiters” Reaching for the NoDoz in 2011 The consensus is that 2011 will be a bad year for big pharma.  It must confront a breaking wave of patent expirations, while fiscal retrenchment has created an innovation cycle in reverse as payers find new ways […]
Posted in compliance, Manufacturing, Marketing, R&D, Regulatory, Strategy, Technology | Also tagged , | 5 Comments
  • Categories

  • Meta